COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Monogoto Raises $27 Million in Series A Funding to Lead the Software-Defined Connectivity Revolution
Monogoto secures $27M Series A funding round led by Toyota Ventures, Samsung Next, and others to drive innovation in software-driven, API-based connectivity for connected devices. Co-Founders: Itamar Kunik, CEO; Maor Efrati, CTO -
COMMUNIQUÉ DE PRESSE
Revival Health Inc. Partners With BSS Health to Bring Affordable GLP-1 Obesity Medication to Mississippians Following Policy Change at Mississippi Board of Medical Licensure
Revival Health and former Governor Phil Bryant partner to launch the Mississippi Obesity Alliance Program to combat the state's obesity crisis by providing affordable GLP-1 medications. The program aims to help Mississippians manage and reduce obesity rates -
-
COMMUNIQUÉ DE PRESSE
Varengold Bank ends third quarter with satisfactory result
Varengold Bank AG reports satisfactory results for the third quarter of 2024, with EBT at EUR 14.6 million and net income at EUR 39.5 million. The bank confirms its expected EBT range of EUR 9 to 13 million for the full year 2024 -
COMMUNIQUÉ DE PRESSE
Beyond Oil Expands into Western Europe with Purchase Order from Mister Noodles Restaurant Chain in Spain
Beyond Oil receives first direct purchase order for its product in Western Europe from Mister Noodles, a Spanish restaurant chain with 20 locations, marking a significant milestone in their global expansion strategy -
-
COMMUNIQUÉ DE PRESSE
Lahontan Announces Increase in Mineral Resources at Santa Fe: 1,539,000 Au Eq oz Indicated, and 411,000 Au Eq oz Inferred
Lahontan Gold Corp. announces updated Mineral Resource Estimate for Santa Fe Mine, Nevada, showing significant increases in gold and silver resources. Key findings detailed -
COMMUNIQUÉ DE PRESSE
GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug
EndoPure Life Sciences to finance first-in-human clinical trials for GB Sciences' cannabinoid-based products through exclusive licensing deal. Aging populations drive global demand for treatments of neurological disorders -
